AHA Coding Clinic® for ICD-9 - 1998 Fourth Quarter; VOLUMES 1 & 2 NEW/REVISED CODES
Malignant Hyperthermia
Malignant hyperthermia is an autosomal-dominant inherited disorder. The incidence of genetic predisposition is 1:10000, the clinical incidence about 1:30000. Malignant hyperthermia is a life threatening, acute pharmacogenetic disorder which develops during or after a general anesthesia. Triggering agents include all volatile anesthetics (Chloroform, Ether, Halothane, Enflurane, Isuflurane, Sevoflurane, Deflurane) and depolarizing muscle relaxants. This disorder causes a sudden, rapid rise in body temperature associated with signs of increased muscle metabolism. Other signs and symptoms include tachycardia, arrhythmia, tachypnea, sweating, cyanosis and muscle rigidity. The reaction is rapidly progressive and often fatal. Treatment must be initiated immediately. Prior to October...
Subscribe or sign in to view the full article.
Article Overview
This article discusses malignant hyperthermia as a serious anesthesia-related condition and explains its placement in the ICD-9-CM coding system. It is relevant to coders, clinicians, and compliance staff who need to understand the condition’s general clinical context and the historical code change referenced in the article.
Why This Topic Matters
The topic matters because malignant hyperthermia is a critical perioperative event with coding implications tied to diagnosis classification history and documentation awareness.
What You Will Learn
- The general clinical context of malignant hyperthermia.
- How the article situates the condition within ICD-9-CM classification history.
- Why the condition is important from a coding and documentation perspective.
- The broader anesthesia-related setting in which the condition occurs.
Who Should Read This
- Medical coders
- Coding educators
- Clinical documentation staff
- Perioperative clinicians
- Compliance reviewers
Codes Discussed
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com